PHERGain and PHERGain-2 advance therapeutic de-escalation in early HER2-positive breast cancer in selected patients

Data ReadoutpositivePositive

AI Analysis

Summary

PHERGain and PHERGain-2 trial results demonstrate that a two-drug targeted therapy combination enables approximately one-third of early HER2-positive breast cancer patients to avoid chemotherapy while achieving ~90% five-year disease-free survival rates post-surgery.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

PHERGain study results confirm combination of two targeted agents allows one-third of patients to be treated without chemotherapy with disease-free survival rates close to 90% at five years post-surgery. PHERGain-2 trial published simultaneously.

Importance:7/10

Sentiment:

0.80

HER2-positive breast cancerde-escalation therapytargeted agentschemotherapy-free treatmentdisease-free survival

Read the original article

Published by PR Newswire Pharma on May 7, 2026 10:14 AM

Read Original